Brief: Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz® (Aminolevulinic Acid HCI) Topical Gel
25/08/2025 13:30
Aug 25 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA INC. ANNOUNCES LAST-PATIENT-OUT IN PHASE 2B STUDY OF AMELUZ® (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS BIOFRONTERA INC - TOP-LINE RESULTS EXPECTED Q1 2026 BIOFRONTERA INC - FDA DISCUSSION PLANNED Q3 2026 FOR PHASE 3 PROGRAM Source text: ID:nGNX31pqSK Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales